OncoC4, Inc.
Privately held: no public share price · United States
Assets
(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | CTLA-4Monoclonal antibody | Non-Small Cell Lung Cancer | |
| Phase 1 | PD-1 x CTLA-4Combination | Non-Small Cell Lung Cancer |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (2)
November 2026 (1)
Est. primary completion 2026-11-30 · NCT05682443 · CT.gov ↗
What to watch
December 2026 (1)
GotistobartPhase 1/2Non Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Melanoma, Metastatic Head and Neck Carcinoma, Metastatic Renal Cell Carcinoma …
Est. primary completion 2026-12-31 · NCT04140526 · CT.gov ↗
What to watch
2027 (1)
August 2027 (1)
Est. primary completion 2027-08-31 · NCT05671510 · CT.gov ↗
What to watch
2036 (1)
July 2036 (1)
Est. primary completion 2036-07-01 · NCT07659379 · CT.gov ↗
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
BioNTech SE and OncoC4, Inc. · Source ↗
Financial reports
No financial reports recorded.